Cadent Therapeutics Stock

cadenttx.comHealthcareFounded: 2010Funding to Date: $67.4MM

Developer of a drug development platform intended to focus on medicines for psychiatric diseases. The company's platform develops small molecule therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders, schizophrenia and other cognitive and neuropsychiatric disorders, enabling patients to cure various neurological diseases.

Register for Details

For more details on financing and valuation for Cadent Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Cadent Therapeutics.

Register Today

Team

Management Team

Timothy Piser Ph.D
Chief Scientific Officer
David Anderson Ph.D
Head of Discovery Operations
John McBride
Chief Financial Officer
Robert Volkmann Ph.D
Vice President of Chemistry & Advisor
Michael Curtis Ph.D
President & Chief Executive Officer
Christopher Kenney
Chief Medical Officer

Board Members

Daniel Behr
Mark McDade
Qiming Venture Partners
Richard Horan
Slater Technology Fund
Benjamin Bronstein MD
Clal Biotechnology Industries
Franz Hefti
Cadent Therapeutics
Paul Wotton Ph.D
Timothy Anderson
Cowen Group
David Grayzel MD
Atlas Venture
James Bristol Ph.D
Peter Barrett Ph.D
Atlas Venture
William Koster Ph.D
Clal Biotechnology Industries

Other companies like Cadent Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM